You Position: Home > Paper
A CLINICAL STUDY OF TENIPOSIDE-BASED COMBINATIVE CHEMOTHERAPEUTIC REGIMENS IN THE TREATMENT OF ACUTE LEUKEMIA CROSS-EXPRESSING LINEAGE-ASSOCIATED ANTIGEN
( views:189, downloads:16 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1009-9921.2003.05.004
- Key Word:
- 替尼泊苷;化学治疗;白血病,急性;分化抗原,髓系,淋系
Abstract： 目的:探讨替尼泊苷联合方案治疗交叉表达淋系和髓系抗原急性白血病的化疗疗效.方法:应用替尼泊苷联合阿糖胞苷、环磷酰胺、长春地辛及泼尼松组成TA或TA+COP方案,治疗伴淋系抗原表达的急性髓细胞白血病(Ly+AML)24例和伴髓系抗原表达的急性淋巴细胞白血病(My+ALL)17例.结果:完全缓解(CR)率为56.1%(23/41),总有效率为80.5%(33/41).与常规方案(DA、VDLP)诱导疗效相比有显著性差异(P＜0.01).其中Ly+AML的CR率为58.3%,总有效率为79.2%;My+ALL的CR率为52.9%,总有效率为82.4%.复治性Ly+AML/My+ALL总有效率为72.7%(8/11).两种方案的骨髓抑制明显,毒副作用能够耐受.结论:Ly+AML和My+ALL不宜采用常规诱导缓解方案,TA和TACOP方案宜作为此类患者的首选治疗方案.
- [1]黄一虹,李德鹏,主鸿鹄,等.淋系分化抗原在急性髓细胞白血病中的表达及其意义[J].2000,(2).
- [2]李伟,苏伟,胡凯文,等.急性白血病P170和CD34抗原表达及其临床意义[J].2001,(3).
- [3]张之南.血液病诊断及疗效标准[M].1998.
- [4]P W, Feldhoff,S E, Mirski,S P, Cole,etc.Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.[J].1994,54.
- [5]马文辉,任波.威猛联合阿糖胞苷治疗难治复发性急性非淋巴细胞性白血病观察[J].1998,(5).
- [6]M C, Bene,G, Castoldi,W, Knapp,etc.Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).[J].1995,9.
- [7]K.R Hande.Etoposide: four decades of development of a topoisomerase II inhibitor[J].1998,34(10).
- [8]A, Cuneo,J L, Michaux,A, Ferrant,etc.Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers.[J].1992,79.
- [9]G R, Bicknell,R T, Snowden,G M, Cohen.Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukaemic cell line, U937.[J].1994,107 ( Pt 9).
- [10]D. Catovsky,E. Matutes,V. Buccheri,etc.A classification of acute leukaemia for the 1990s[J].1991,62(1).